Skip to main content
Aarti Pharmalabs Limited logo

Aarti Pharmalabs Limited — Investor Relations & Filings

Ticker · AARTIPHARM ISIN · INE0LRU01027 LEI · 335800TTAKRBNDK5P363 BSE.NS Manufacturing
Open in API
Filings indexed 246 across all filing types
Latest filing 2024-10-28 Regulatory Filings
Country IN India
Listing BSE.NS AARTIPHARM

About Aarti Pharmalabs Limited

https://www.aartipharmalabs.com/

Aarti Pharmalabs Limited is a manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and xanthine derivatives. The company specializes in the development and production of complex chemistry-based products for the global pharmaceutical and generic drug industries. Its core portfolio includes APIs across diverse therapeutic areas such as oncology, cardiovascular, and anti-diabetics. Additionally, the company is a major producer of xanthines, including caffeine and theophylline. Aarti Pharmalabs offers comprehensive Contract Development and Manufacturing Organization (CDMO) services, leveraging its integrated research and development capabilities and large-scale manufacturing facilities. The organization maintains high regulatory standards, ensuring compliance with international quality benchmarks to serve a global clientele.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges regarding the recording of an earnings conference call. It references Regulation 30 of SEBI (LODR) Regulations 2015 and provides a link to the audio recording of the call for the quarter and half year ended September 30, 2024. The document does not contain the transcript or detailed financial data but is an announcement about the availability of the call recording. Given the short length (1307 characters) and the nature of the content, this is not the call transcript itself but an announcement related to it. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a full Call Transcript (CT).
2024-10-28 English
Resignation
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding the resignation of the Company Secretary and Compliance Officer, Mr. Nikhil Natu. It references Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to disclosure of events or information by listed entities. The content includes details about the resignation, effective date, and related annexures. There is no financial data, earnings information, or report publication mentioned. The document is clearly an announcement of a management change, specifically a key managerial personnel resignation, which fits the category of Board/Management Information (MANG). The document length is 2851 characters, which is short and consistent with an announcement rather than a full report.
2024-10-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 95% confidence The document is a detailed presentation titled 'Q2/H1 FY25 Results Presentation' addressed to stock exchanges and compliance departments, referencing Regulation 30 of SEBI (LODR) Regulations 2015. It contains extensive company overview, business strategy, financial highlights, board of directors information, manufacturing presence, and geographical sales data. The content is consistent with an investor presentation focusing on financials, strategy, and market position rather than a formal financial report or regulatory filing. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, the appropriate classification is 'Investor Presentation' (IP).
2024-10-28 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a formal communication addressed to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting held on October 28, 2024. It specifically mentions the approval of the Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2024, along with the Auditor's Report on these financial results. The document includes detailed financial data such as income, expenses, profit, tax expenses, and earnings per share for the specified periods. The presence of comprehensive financial statements and audit information for a half-year period indicates this is a financial report for a period shorter than a full fiscal year. The document is not merely an announcement of a report but contains substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-10-28 English
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement dated October 28, 2024, from Aarti Pharmalabs Limited addressed to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting. It specifically mentions the approval of the Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2024, along with the Auditor's Report on these financial results. The document includes detailed financial tables with income, expenses, profit, tax, and earnings per share data for the quarter and half year periods, indicating substantive financial data and analysis. The presence of audited quarterly and half-year financial results with detailed figures aligns with the characteristics of an Interim / Quarterly Report (IR). The document is not merely an announcement of a report publication but contains the actual financial results and auditor's report summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2024-10-28 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a formal communication addressed to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting held on October 28, 2024. It references compliance with SEBI (LODR) Regulations, 2015, specifically Regulation 30 and 33, which pertain to disclosure of financial results. The document announces the approval of the Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2024, and includes detailed financial data such as income, expenses, profit, tax expenses, and earnings per share. The presence of detailed audited financial results for a quarter and half year period, along with comprehensive financial figures, indicates this is a quarterly/half-year financial report. The document is about the financial results for a period shorter than a full fiscal year and contains substantive financial data and analysis, which fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report but includes the actual financial results. Therefore, the correct classification is IR with high confidence.
2024-10-28 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.